SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 25,972 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 25,972 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $20.12, for a total transaction of $522,556.64. Following the transaction, the chief executive officer directly owned 291,491 shares of the company’s stock, valued at approximately $5,864,798.92. This represents a 8.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Performance

Shares of SIBN traded down $0.11 during trading hours on Wednesday, reaching $19.43. 601,112 shares of the company traded hands, compared to its average volume of 544,512. The stock’s fifty day moving average is $17.74 and its 200 day moving average is $15.40. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The stock has a market cap of $861.72 million, a P/E ratio of -57.15 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Equities research analysts anticipate that SiBone will post -0.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SiBone

A number of hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its holdings in SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares during the period. Versant Capital Management Inc boosted its holdings in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the last quarter. Larson Financial Group LLC increased its position in shares of SiBone by 42.3% during the fourth quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after buying an additional 1,061 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in SiBone by 4.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after buying an additional 1,459 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SIBN shares. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. UBS Group increased their target price on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. TD Cowen boosted their price target on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Truist Financial reissued a “buy” rating and set a $23.00 price objective (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.